These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

427 related items for PubMed ID: 10335419

  • 1. Development of beta 3-adrenoceptor agonists for the treatment of obesity and diabetes--an update.
    Weyer C, Gautier JF, Danforth E.
    Diabetes Metab; 1999 Mar; 25(1):11-21. PubMed ID: 10335419
    [Abstract] [Full Text] [Related]

  • 2. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans.
    de Souza CJ, Burkey BF.
    Curr Pharm Des; 2001 Sep; 7(14):1433-49. PubMed ID: 11472270
    [Abstract] [Full Text] [Related]

  • 3. Prospects for beta 3-adrenoceptor agonists in the treatment of obesity and diabetes.
    Arch JR, Wilson S.
    Int J Obes Relat Metab Disord; 1996 Mar; 20(3):191-9. PubMed ID: 8653138
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic beta 3-adrenergic agonist.
    Nagase I, Yoshida T, Kumamoto K, Umekawa T, Sakane N, Nikami H, Kawada T, Saito M.
    J Clin Invest; 1996 Jun 15; 97(12):2898-904. PubMed ID: 8675704
    [Abstract] [Full Text] [Related]

  • 6. Anti-obesity and anti-diabetic activities of a new beta3 adrenergic receptor agonist, (S)-(Z)-[4-[[1-[2-[(2-hydroxy-3-phenoxypropyl)]amino]ethyl]-1-propenyl] phenoxy] acetic acid ethanedioic acid (SWR-0342SA), in KK-Ay mice.
    Kiso T, Namikawa T, Tokunaga T, Sawada K, Kakita T, Shogaki T, Ohtsubo Y.
    Biol Pharm Bull; 1999 Oct 15; 22(10):1073-8. PubMed ID: 10549858
    [Abstract] [Full Text] [Related]

  • 7. Learning new tricks from old dogs: beta-adrenergic receptors teach new lessons on firing up adipose tissue metabolism.
    Collins S, Cao W, Robidoux J.
    Mol Endocrinol; 2004 Sep 15; 18(9):2123-31. PubMed ID: 15243132
    [Abstract] [Full Text] [Related]

  • 8. Strain-specific response to beta 3-adrenergic receptor agonist treatment of diet-induced obesity in mice.
    Collins S, Daniel KW, Petro AE, Surwit RS.
    Endocrinology; 1997 Jan 15; 138(1):405-13. PubMed ID: 8977430
    [Abstract] [Full Text] [Related]

  • 9. Discovery of novel thiourea derivatives as potent and selective beta3-adrenergic receptor agonists.
    Maruyama T, Seki N, Onda K, Suzuki T, Kawazoe S, Hayakawa M, Matsui T, Takasu T, Ohta M.
    Bioorg Med Chem; 2009 Aug 01; 17(15):5510-9. PubMed ID: 19581100
    [Abstract] [Full Text] [Related]

  • 10. Evidence for numerous brown adipocytes lacking functional beta 3-adrenoceptors in fat pads from nonhuman primates.
    Viguerie-Bascands N, Bousquet-Mélou A, Galitzky J, Larrouy D, Ricquier D, Berlan M, Casteilla L.
    J Clin Endocrinol Metab; 1996 Jan 01; 81(1):368-75. PubMed ID: 8550779
    [Abstract] [Full Text] [Related]

  • 11. Thermogenesis and related metabolic targets in anti-diabetic therapy.
    Arch JR.
    Handb Exp Pharmacol; 2011 Jan 01; (203):201-55. PubMed ID: 21484574
    [Abstract] [Full Text] [Related]

  • 12. [Beta 3 adrenergic receptor polymorphism and obesity].
    Yoshida T, Umekawa T.
    Nihon Rinsho; 1998 Jul 01; 56(7):1871-5. PubMed ID: 9702068
    [Abstract] [Full Text] [Related]

  • 13. Promising new approaches.
    Reasner CA.
    Diabetes Obes Metab; 1999 May 01; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [Abstract] [Full Text] [Related]

  • 14. The effects of beta(3)-adrenoceptor agonist CL-316,243 on adiponectin, adiponectin receptors and tumor necrosis factor-alpha expressions in adipose tissues of obese diabetic KKAy mice.
    Fu L, Isobe K, Zeng Q, Suzukawa K, Takekoshi K, Kawakami Y.
    Eur J Pharmacol; 2008 Apr 14; 584(1):202-6. PubMed ID: 18304529
    [Abstract] [Full Text] [Related]

  • 15. Beta-3 adrenergic receptor agonists cause an increase in gastrointestinal transit time in wild-type mice, but not in mice lacking the beta-3 adrenergic receptor.
    Fletcher DS, Candelore MR, Grujic D, Lowell BB, Luell S, Susulic VS, Macintyre DE.
    J Pharmacol Exp Ther; 1998 Nov 14; 287(2):720-4. PubMed ID: 9808702
    [Abstract] [Full Text] [Related]

  • 16. Appearance of brown adipocytes in white adipose tissue during CL 316,243-induced reversal of obesity and diabetes in Zucker fa/fa rats.
    Ghorbani M, Himms-Hagen J.
    Int J Obes Relat Metab Disord; 1997 Jun 14; 21(6):465-75. PubMed ID: 9192230
    [Abstract] [Full Text] [Related]

  • 17. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
    Arch JR.
    Eur J Pharmacol; 2002 Apr 12; 440(2-3):99-107. PubMed ID: 12007528
    [Abstract] [Full Text] [Related]

  • 18. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 12; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 19. Advances in pharmacotherapy for obesity.
    Carruba M, Tomello C, Briscini L, Nisoli E.
    Int J Obes Relat Metab Disord; 1998 Aug 12; 22 Suppl 1():S13-6; discussion S17. PubMed ID: 9758239
    [Abstract] [Full Text] [Related]

  • 20. Antiobesity and antidiabetic beta-agonists: lessons learned and questions to be answered.
    Yen TT.
    Obes Res; 1994 Sep 12; 2(5):472-80. PubMed ID: 16353599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.